Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Bispecific Antibodies in the Treatment of Multiple Myeloma: Expert and Patient Perspectives : Episode 7

Discussing Consent for Supportive Care Agents with Patients with Multiple Myeloma

February 22, 2023
By Ajai Chari, MD
Annel Urena
  • Kiah Purcell

Video

Nurse Practitioner Kiah Purcell explains how she discusses supportive care agents with patients receiving a BCMA-targeting bispecific for multiple myeloma in case a patient experiences cytokine release syndrome.

EP: 1.A Patient’s Experience With a Multiple Myeloma Diagnosis

EP: 2.Resources for Patient Education

EP: 3.Patient Experience With Treatment for Multiple Myeloma and Clinical Trial Participation

EP: 4.The Role of Teclistamab in Multiple Myeloma

EP: 5.Process of Administering Teclistamab and Other Bispecific Agents

EP: 6.Step-Up Doses in Patients Receiving Teclistamab for Multiple Myeloma

Now Viewing

EP: 7.Discussing Consent for Supportive Care Agents with Patients with Multiple Myeloma

EP: 8.Advice to Patients with Multiple Myeloma Facing Hospital Admission For Teclistamab Therapy

EP: 9.Counseling Patients Receiving Teclistamab for Multiple Myeloma on COVID Precautions

EP: 10.Counseling Patients with Multiple Myeloma on the Infection Risks of BCMA-Targeting Bispecifics

EP: 11.CAR T-Cell Therapy in Multiple Myeloma and Quality of Life

EP: 12.Advice for Patients, Nurse Practitioners, and Community Oncologists on Teclistamab Therapy in Multiple Myeloma

EP: 13.Recap: Teclistamab in Multiple Myeloma: A Patient’s Journey

Recent Videos
Related Content
Advertisement

Developers designed cemsidomide as an orally bioavailable small molecule degrader that targets IKZF1/3, which drive multiple myeloma and non-Hodgkin lymphoma.

Cemsidomide Combo May Produce Responses in Multiple Myeloma

Russ Conroy
May 8th 2025
Article

Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.


Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.


"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.

Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma

Russ Conroy
May 3rd 2025
Article

Extramedullary disease was the only factor that correlated with worse progression-free survival per multivariate analysis.


James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.


“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.

Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

Russ Conroy
April 28th 2025
Article

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.


Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM

Roman Fabbricatore
April 27th 2025
Article

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

Related Content
Advertisement

Developers designed cemsidomide as an orally bioavailable small molecule degrader that targets IKZF1/3, which drive multiple myeloma and non-Hodgkin lymphoma.

Cemsidomide Combo May Produce Responses in Multiple Myeloma

Russ Conroy
May 8th 2025
Article

Investigators of the phase 1/2 CFT7455-1101 study have determined cemsidomide at a dose of 100 µg safe for expansion.


Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.


"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.

Salvage Isatuximab Combo Elicits Efficacy in Lenalidomide-Relapsed Myeloma

Russ Conroy
May 3rd 2025
Article

Extramedullary disease was the only factor that correlated with worse progression-free survival per multivariate analysis.


James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.


“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.

Mortality, Adverse Outcome Odds Higher in Multiple Myeloma PEM Population

Russ Conroy
April 28th 2025
Article

Findings indicate a need to address protein-energy malnutrition in the treatment of those who have multiple myeloma with acute congestive heart failure.


Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM

Roman Fabbricatore
April 27th 2025
Article

Treatment with daratumumab-based combination therapies may drive minimal residual disease conversion rates in patients with newly diagnosed multiple myeloma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.